Risk/benefit ratio of perioperative OKT3 in cardiac transplantation.
This study shows that perioperative OKT3 provides no benefit in terms of the time of onset or frequency of rejection or patient survival. However, it does result in an increased incidence of infection, particularly CMV infection. Thus, the risk/benefit ratio of perioperative OKT3 does not appear favorable. However, a multicenter, randomized trial including a larger number of patients and longer patient follow-up will be required to definitively answer the question.
Johnson
M R
MR
Department of Medicine, Loyola University Medical Center, Maywood, Illinois 60153.
Mullen
G M
GM
O'Sullivan
E J
EJ
Liao
Y
Y
Heroux
A L
AL
Kao
W
W
Pifarre
R
R
Costanzo-Nordin
M R
MR
D001379:Azathioprine / Q000627:therapeutic use; D016572:Cyclosporine / Q000627:therapeutic use; D005260:Female; D006084:Graft Rejection / Q000276:immunology / Q000473:pathology; D016027:Heart Transplantation / Q000276:immunology* / Q000473:pathology / Q000502:physiology; D006801:Humans; D007165:Immunosuppression Therapy / Q000379:methods; D007432:Intraoperative Period; D008297:Male; D008775:Methylprednisolone / Q000627:therapeutic use; D008875:Middle Aged; D016853:Muromonab-CD3 / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D011241:Prednisone / Q000627:therapeutic use; D012189:Retrospective Studies; D013601:T-Lymphocytes / Q000276:immunology; D016896:Treatment Outcome
D016853:Muromonab-CD3; D016572:Cyclosporine; D001379:Azathioprine; D011241:Prednisone; D008775:Methylprednisolone